Phase III Trial of Enzastaurin for NHL Patients Initiated

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Phase III Trial of Enzastaurin for NHL Patients Initiated

INDIANAPOLIS—Eli Lilly has initiated a randomized, placebo- controlled phase III trial of its experimental agent enzastaurin as maintenance therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL) who have achieved remission after first-line therapy. In early clinical studies, enzastaurin, an oral serinethreonine kinase inhibitor, showed promising activity in NHL.

Articles in this issue
Surgeons Perform Remote Robotic Animal Nephrectomy Over Public Internet: A First
High-Quality Screening Colonoscopy Priority for GI Docs
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Denosumab Suppresses Bone Resorption in Breast Ca Mets
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)
FDA Approves Revlimid for Myeloma Rx
Real-Time RT Planning, Delivery in the Bronx
Phase III Trial of Enzastaurin for NHL Patients Initiated
Dr. Niederhuber, New Acting Director of NCI, Confronts the Old Problem of an Ever-Declining Institute Budget
Racial Disparities in Prostate Ca Recurrence
HNPCC Pts May Reject Prophylactic Subtotal Colectomy
Improved Colonoscopy Techniques Increase Patient Comfort
New Agents Top Standard Rx in First-Line Advanced RCC
Two Cancer Bills Introduced in the US House of Representatives
Interventions Increase Chemotherapy Center Capacity
Recent Videos
Epcoritamab Demonstrates Complete Responses at 2 Years in R/R LBCL
Epcoritamab Demonstrates Complete Responses at 2 Years in R/R LBCL
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
IMNN-001 May Show Enhanced Benefit in HRD-Positive Ovarian Cancer Subgroup
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
Unique Properties of ISB 2001 May Offer Benefits in R/R Multiple Myeloma
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Gene Assay Can Guide Chemo Strategies in Older Breast Cancer Population
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Targeted Tool May Optimize Infusion Therapy Delivery in Breast Cancer
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Pivotal Presentations That May Shape the Breast Cancer Standard of Care
The Role of Molecular Testing in Ovarian Cancer Care
The Role of Molecular Testing in Ovarian Cancer Care
Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
Managing Recurrent Ovarian Cancer: Tailoring Approaches Based on Platinum Sensitivity
Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
Managing Expectations: Adverse Events With Melanoma Immunotherapy
Managing Expectations: Adverse Events With Melanoma Immunotherapy
Related Content
Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

Tony Berberabe, MPH
June 4th 2025
Article

The combination of olaparib and radium-223 improved rPFS in castration-resistant prostate cancer without prior docetaxel treatment or with fewer than 20 bone metastases.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Machine Learning Approach May Predict Outcomes in RCC

Kristie L. Kahl
June 4th 2025
Article

A machine learning-based approach found that evaluating multiple biomarker features may identify outcomes and treatment resistance in renal cell carcinoma.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.

PFS, OS Numerically Improve Via IMNN-001 Combo in Epithelial Ovarian Cancer

Chris Ryan
June 4th 2025
Article

Investigators of the OVATION-2 trial assessed IMNN-001, a novel IL-2 gene therapy, in patients with newly diagnosed epithelial ovarian cancer.

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.

Rechallenge With RET Inhibitors Shows Efficacy in Pre-Treated NSCLC

Roman Fabbricatore
June 4th 2025
Article

RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.